Abstract
Objectives: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Aβ) and tau proteins in the pathogenic cascade leading to onset of Alzheimers disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. Methods: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by highresolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [18F]fluoroethyl-DAA1106. Results: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Aβ, AβN3pE. As levels of this Aβ subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Aβ antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. Conclusions: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.
Keywords: Amyloid, Aβ, tau, transgenic mouse, positron emission tomography, microglia, imaging biomarker
Current Alzheimer Research
Title: Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Makoto Higuchi
Affiliation:
Keywords: Amyloid, Aβ, tau, transgenic mouse, positron emission tomography, microglia, imaging biomarker
Abstract: Objectives: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Aβ) and tau proteins in the pathogenic cascade leading to onset of Alzheimers disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. Methods: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by highresolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [18F]fluoroethyl-DAA1106. Results: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Aβ, AβN3pE. As levels of this Aβ subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Aβ antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. Conclusions: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.
Export Options
About this article
Cite this article as:
Higuchi Makoto, Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602906
DOI https://dx.doi.org/10.2174/156720509787602906 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews Inflammation and Inflammatory Cell Recruitment in Acute Cerebrovascular Diseases
Current Immunology Reviews (Discontinued) Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology Association of Newly Diagnosed Hypertension and Polypharmacy with Frailty in a Tertiary Hospital Patients from Maracaibo City, Venezuela
Current Hypertension Reviews Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents
Mini-Reviews in Medicinal Chemistry Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Psychological Interventions for Neuropsychiatric Disturbances in Mild and Moderate Alzheimer’s Disease: Current Evidences and Future Directions
Current Alzheimer Research Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases
Current Alzheimer Research NADPH Oxidase and Neurodegeneration
Current Neuropharmacology